A randomized, double-blind phase IIIb study to evaluate the safety and efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate versus Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir disoproxil fumarate in HIV-1 infected, antiretroviral treatment-naïve women

Project no.: HIV-NAT 195/GF-US-236-0128 (WAVES) (NCT01705574)

Randomized, double-blinded, multicenter, active-controlled study to evaluate the safety and efficacy of a regimen containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) administered as a single tablet regimen (STR) versus ritonavir-boosted atazanavir (ATV/r) plus emtricitabine/tenofovir disoproxil fumarate (Truvada® or FTC/TDF) in HIV 1 infected, antiretroviral treatment-naïve adult women.